Triton Investment Management announced on December 8, 2021 a recommended cash offer to acquire the entire issued and to be issued share capital of Clinigen Group plc for 925p per share, valuing Clinigen at an enterprise value of approximately £1.6 billion. The StepStone Group is participating in the transaction as a passive co-investor, with an indirect interest in Triton’s Bidco through a fund managed by Triton.
Clinigen operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets.
RBC acted as Lead Financial Advisor to Clinigen.
